NIDAN LABORATORIES AND HEALTH (NIDAN): Financials & Fundamentals History

Share Price

₹13.00

P/E

11.9x

ROCE

6.0%

Market Cap

₹18 cr

Revenue (TTM)

₹26 cr

P/S

0.7x

P/B

0.3x

ROE

2.2%

Debt / Equity

0.2x

Promoter Holding

57.0%

12M Momentum

-30.1%

P/E vs its own history19th percentilesince Nov '21

P/E vs Health Services0.3xthe sector median

52-week range

₹11.50₹24.90

11% of the way from its 52-week low to its high

Price risk

1Y volatility

59.0%

Beta vs sector

1-year daily

0.63

Balance sheet & cash

Interest cover

operating profit ÷ interest

2.2x

Cash from profit, 3Y

operating cash flow ÷ net profit

5.00x

Share count, 1Y

unchanged

Was the rally earned?

1 year3 years

-30%share price, 1 yearEarnings-driven

Mostly earnings.

Per-share earnings took off 22 points, while the multiple moved less (P/E 13.1x to 11.9x).
The share count barely moved.

Net profit growth-22 ptsNet profit fell about 23%, which lowers the price.

P/E change-8 ptsThe P/E fell from 13.1x to 11.9x, which lowers the price.

Share count change0 ptsShare count was little changed. More shares would count against the price.

-59%share price, 3 yearsEarnings-driven

Mostly earnings.

Per-share earnings took off 56 points, while the multiple moved less (P/E 12.3x to 11.9x).
The share count barely moved.

Net profit growth-56 ptsNet profit fell about 57%, which lowers the price.

P/E change-2 ptsThe P/E fell from 12.3x to 11.9x, which lowers the price.

Share count change0 ptsShare count was little changed. More shares would count against the price.

What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Not shown for 5 years: earnings were negative at one end, or there is not enough history.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with DR. LAL PATHLABS

Is it expensive against its own past and its peers?

11.9xP/E todayNear its historic low

Against its own history19th percentileMedian 14.4x; usual range 11.2x to 25.4x since 2021-11.

Against Health Services11.9x vs 46.4xBelow the Health Services median.

P/EP/BP/S

P/E (this company)10th to 90th percentile of its own historyIts medianHealth Services median

The chart loads when you open this tab.

P/B (this company)10th to 90th percentile of its own historyIts medianHealth Services median

The chart loads when you open this tab.

P/S (this company)10th to 90th percentile of its own historyIts medianHealth Services median

How to read this

Shaded band: 10th to 90th percentile of the company's own P/E history; dashed line: its median; orange line: sector median (companies with a positive multiple, at least 5 in the sector).

Sector figures are built from today's listed companies, so they exclude companies that are no longer listed.

All terms explained in the glossary →

How Health Services is valued

What is the price implying?

~11%annual earnings growth implied by the price

At a P/E of 13.9x, the price would imply about 11.2%/yr earnings growth for 10 years under the same assumptions, but it is not ranked.

Below the ₹1,000 cr market-cap floor used for the lists.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect.

What prices imply across Health Services The market-wide Expectations lists

What changed?

Oct '26Fell 90% from the Nov 2021 peak to the Oct 2026 low.
Jun '26Year-on-year EPS growth turned negative.
Jan '26P/E fell below the 10th percentile of its own history to date (10.7x).
Jun '25EPS (TTM) turned positive.
Jun '24Promoter holding fell 5.8 pts to 57.0% (largest drop since 2023-12).
Jun '24EPS (TTM) turned negative.
Jun '24Slipped to the bottom quartile of Health Services on EPS growth (from the 2nd quartile).
Mar '24P/E fell below the 10th percentile of its own history to date (10.6x).

Show 8 earlier events

Dec '23Promoter holding fell 8.4 pts to 62.8%.
Nov '23P/E fell below the 10th percentile of its own history to date (13.1x).
Jun '23Year-on-year EPS growth turned positive.
Jun '23Slipped to the bottom quartile of Health Services on ROCE (from the 3rd quartile).
Nov '22Debt / equity halved over 12 months to 0.29x.
Nov '22Share count is up 40.4% over 12 months.
Jun '22Slipped to the 3rd quartile of Health Services on ROCE (from the 2nd quartile).
Jun '22Debt / equity fell below 1.0x (0.29x).

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Are profits backed by cash?

4 of 5 checks are within range, 1 beyond a threshold.
Tap a check to see how it is measured.

Other income reliance60%Beyond threshold

Other income as a share of pre-tax profit (trailing twelve months): 59.8%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate—Not enough data

Not enough reported data to compute this.

Cash conversion36.73xWithin range

Operating cash flow divided by net profit over the last three fiscal years: 36.73x (cash from operations ₹9.5 cr, net profit ₹0.3 cr). Bands: 0.8x and above, 0.5x to 0.8x, below 0.5x.

Free cash flow5 of 5 yrsWithin range

Fiscal years with positive free cash flow in the last 5: 5. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history+13 daysWithin range

Debtor days are above the median of the previous three fiscal years by 13 days (32 vs 19). Bands: under 15 days, 15 to 45, over 45.

Capital work in progress1% of fixed assetsWithin range

Capital work-in-progress is 1% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days—Not enough data

Not enough reported data to compute this.

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

Over 3 years, promoters trimmed 5.8 pts.
The number of shareholders fell from 2,791 to 2,359 (-15%) between Mar 2022 and Jun 2026.

Holdings, Jun '26

How each group changed

GroupMar '22Jun '26Change

Promoters71.2%57.0%-14.2 pts

FIIs———

DIIs———

Public and others28.8%43.0%+14.2 pts

Number of shareholders

2,359shareholders-15% since Mar '22

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

How rough has the ride been?

Maximum drawdown-89.6%not yet recovered

1-year volatility59.0%annualised

Monthly share price

Last 90 trading days

Drawdown from peak

Largest drawdowns

-89.6% (2021-11 peak to 2026-10 low, not yet recovered)

Where does it rank among Health Services peers?

Each cell is the company's percentile rank among its Health Services peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

ROCE

Revenue growth

EPS growth

Debt/equity ↓

Cash cycle ↓

P/E ↓

12M momentum

Nov '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Oct '26

Lower rank Higher rank Not enough data

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Services sector page Watch it move against Health Services in the Observatory

What happened next to similar setups

+25.6%typical 12-month return vs the marketAbove the base rate

We found 50 past situations where a non-financial company looked like NIDAN LABORATORIES AND HEALTH today on valuation, return on capital, debt, growth, price momentum and size.
Over the following 12 months the middle half of them returned −17% to +74% vs the market, against −4% for all non-financial companies in the same months.
The analogs' median sat above that base rate (gap +29.7%, 80% range +9.9% to +38.9%), but the matches cluster in only 6 distinct 12-month windows.

Where the 50 outcomes landed

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 10 beyond the range shown, drawn at the edge

Similar setups' median

+25.6%

All companies' median

−4.1%

Beat the market

62% vs 46%

50 past situations · 50 companies · 33 months · 2020–2025

The closest matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
RILINFRA Industrial Services	Oct 2025	17x	7%	−26%	−33%	−9%
TERASOFT Technology Services	Feb 2024	21x	—	+49%	−26%	+205%
DHRUV Industrial Services	Jul 2023	16x	—	−2%	−29%	+71%
SOMICONVEY Producer Manufacturing	Mar 2020	7x	7%	−60%	−68%	+75%
GUJRAFFIA Process Industries	Oct 2023	17x	7%	+9%	−21%	−2%

Show the other 3 matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
ALMONDZ Finance	May 2020	4x	7%	−47%	−58%	+125%
MADHAV Non-Energy Minerals	Aug 2020	11x	3%	−11%	−36%	+54%
AAKASH Energy Minerals	Oct 2025	18x	—	−22%	−32%	−9%

How reliable is this?

Matched on P/E, P/S, ROCE, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high and size. Closest on: 12-month momentum, drawdown from 12-month high and revenue growth. Not used (unavailable for this company): operating margin and volatility. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to NIDAN LABORATORIES AND HEALTH. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-10-30. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

Feature	Weight	Non-financial	Financial
P/E	1	yes	yes
P/S	1	yes	—
P/B	1	—	yes
ROCE	1	yes	—
operating margin	1	yes	—
ROE	1	—	yes
debt/equity	0.75	yes	—
interest cover	0.5	yes	—
revenue growth	0.75	yes	yes
12-month momentum	1	yes	yes
drawdown from 12-month high	0.75	yes	yes
size	0.75	yes	yes
volatility	0.5	yes	yes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
Pools: non-financial: 97,430 company-months from 2000 companies; financial: 5,632 company-months from 106 companies. 2240 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Monthly history (60 months)

Month	P/E	Revenue (TTM)	ROE	ROCE	Debt / Equity
2026-10	11.9x	₹26 cr	2.2%	6.0%	0.2x
2026-09	11.5x	₹26 cr	2.2%	6.0%	0.2x
2026-08	12.1x	₹26 cr	2.2%	6.0%	0.2x
2026-07	12.3x	₹26 cr	2.2%	6.0%	0.2x
2026-06	12.0x	₹26 cr	2.2%	6.0%	0.2x
2026-05	10.2x	₹25 cr	2.9%	6.2%	0.2x
2026-04	10.6x	₹25 cr	2.9%	6.2%	0.2x
2026-03	9.0x	₹25 cr	2.9%	6.2%	0.2x
2026-02	11.3x	₹25 cr	2.9%	6.2%	0.2x
2026-01	10.7x	₹25 cr	2.9%	6.2%	0.2x
2025-12	13.1x	₹25 cr	2.9%	6.2%	0.2x
2025-11	16.1x	₹25 cr	2.9%	6.2%	0.2x
2025-10	13.1x	₹25 cr	2.9%	6.2%	0.2x
2025-09	12.9x	₹25 cr	2.9%	6.2%	0.2x
2025-08	12.7x	₹25 cr	2.9%	6.2%	0.2x
2025-07	14.4x	₹25 cr	2.9%	6.2%	0.2x
2025-06	15.0x	₹25 cr	2.9%	6.2%	0.2x
2025-05	—	₹24 cr	-4.9%	8.0%	0.2x
2025-04	—	₹24 cr	-4.9%	8.0%	0.2x
2025-03	—	₹24 cr	-4.9%	8.0%	0.2x
2025-02	—	₹24 cr	-4.9%	8.0%	0.2x
2025-01	—	₹24 cr	-4.9%	8.0%	0.2x
2024-12	—	₹24 cr	-4.9%	8.0%	0.2x
2024-11	—	₹24 cr	-4.9%	8.0%	0.2x
2024-10	—	₹24 cr	-4.9%	8.0%	0.2x
2024-09	—	₹24 cr	-4.9%	8.0%	0.2x
2024-08	—	₹24 cr	-4.9%	8.0%	0.2x
2024-07	—	₹24 cr	-4.9%	8.0%	0.2x
2024-06	—	₹24 cr	-4.9%	8.0%	0.2x
2024-05	13.3x	₹24 cr	5.1%	8.2%	0.2x
2024-04	11.5x	₹24 cr	5.1%	8.2%	0.2x
2024-03	10.6x	₹24 cr	5.1%	8.2%	0.2x
2024-02	13.2x	₹24 cr	5.1%	8.2%	0.2x
2024-01	14.4x	₹24 cr	5.1%	8.2%	0.2x
2023-12	13.1x	₹24 cr	5.1%	8.2%	0.2x
2023-11	13.1x	₹24 cr	5.1%	8.2%	0.2x
2023-10	12.3x	₹24 cr	5.1%	8.2%	0.2x
2023-09	12.2x	₹24 cr	5.1%	8.2%	0.2x
2023-08	14.9x	₹24 cr	5.1%	8.2%	0.2x
2023-07	16.5x	₹24 cr	5.1%	8.2%	0.2x
2023-06	17.3x	₹24 cr	5.1%	8.2%	0.2x
2023-05	22.7x	₹30 cr	4.0%	10.1%	0.3x
2023-04	21.9x	₹30 cr	4.0%	10.1%	0.3x
2023-03	17.7x	₹30 cr	4.0%	10.1%	0.3x
2023-02	23.0x	₹30 cr	4.0%	10.1%	0.3x
2023-01	26.2x	₹30 cr	4.0%	10.1%	0.3x
2022-12	25.2x	₹30 cr	4.0%	10.1%	0.3x
2022-11	28.1x	₹30 cr	4.0%	10.1%	0.3x
2022-10	28.5x	₹30 cr	4.0%	10.1%	0.3x
2022-09	31.8x	₹30 cr	4.0%	10.1%	0.3x
2022-08	24.5x	₹30 cr	4.0%	10.1%	0.3x
2022-07	17.2x	₹30 cr	4.0%	10.1%	0.3x
2022-06	18.1x	₹30 cr	4.0%	10.1%	0.3x
2022-05	15.9x	₹20 cr	17.3%	14.0%	2.9x
2022-04	17.7x	₹20 cr	17.3%	14.0%	2.9x
2022-03	14.3x	₹20 cr	17.3%	14.0%	2.9x
2022-02	17.7x	₹20 cr	17.3%	14.0%	2.9x
2022-01	21.9x	₹20 cr	17.3%	14.0%	2.9x
2021-12	22.2x	₹20 cr	17.3%	14.0%	2.9x
2021-11	26.0x	₹20 cr	17.3%	14.0%	2.9x

Methodology and data notes